Multiple Myeloma

Midwest CEPAC

ICER plans to assess the comparative clinical effectiveness and value of idecabtagene vicleucel (Bristol-Myers Squibb, bluebird bio) and ciltacabtagene autoleucel  (Johnson & Johnson, Legend Biotech Corp) for the treatment of multiple myeloma. An FDA decision on idecabtagene vicleucel is expected in early 2021. A BLA submission for ciltacabtagene autoleucel is expected by end of 2020.

Date of review: April 2021

For questions or additional information, please contact zodhiambo@icer-review.org.

ASSOCIATED MEETING & MATERIALS

Midwest CEPAC
April 16, 2021 10am-3pm

Virtual

Key Dates

Associated Materials

08/31/2020 – 09/17/2020

09/22/2020

09/22/2020 – 10/13/2020
Public Comments

09/22/2020

10/21/2020
Revised Scoping Document

10/28/2020
Research Protocol

12/17/2020
Model Analysis Plan

02/11/2021
Draft Evidence Report

02/11/2021
Draft Voting Questions

02/11/2021 – 03/11/2021
Public Comments

04/02/2021
Revised Voting Questions

04/02/2021
Response to Public Comments

04/02/2021
Evidence Report

04/16/2021
Meeting Agenda

04/16/2021
Evidence Presentation

05/07/2021
Final Evidence Report and Meeting Summary

05/07/2021
Report-at-a-Glance

05/07/2021
Final Policy Recommendations


ASSOCIATED MEETING & MATERIALS

At its inaugural meeting, the Midwest CEPAC convened to discuss the comparative clinical effectiveness and value of therapies for multiple myeloma.

Key Dates

Associated Materials

02/05/2016

03/08/2016

03/08/2016

03/08/2016

04/07/2016

04/07/2016

05/06/2016

05/06/2016

05/06/2016

Public comments received on ICER’s Draft Evidence Report


05/06/2016

A summary of comments received on ICER’s report on treatments for multiple myeloma, and ICER’s response to comments.